Showing 1051-1060 of 1576 results for "".
- ReVision Therapeutics Announces License With Cornell to Develop Treatment for Stargardt Diseasehttps://modernod.com/news/revision-therapeutics-announces-license-with-cornell-to-develop-treatment-for-stargardt-disease/2478230/ReVision Therapeutics announced that it has signed an exclusive license agreement with Cornell University for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic d
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- Antibody-based eye drops show promise for treating dry eye diseasehttps://modernod.com/news/antibody-based-eye-drops-show-promise-for-treating-dry-eye-disease/2477005/Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid. They are also the first to demonstrate that patients with dry eye d
- Sight Sciences Raises $56M to Lead the Development of MIGS Market and Procedure-Based Dry Eye Markethttps://modernod.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/Sight Sciences announced the closing of $31 million in Series D Preferred Stock financing. MidCap Financial and Sight Sciences entered into a $25 million debt facility earlier in 2019. The $56 million
- Aggressive Steroid Therapy Improves Visual Outcomes in Vogt-Koyanagi-Harada Diseasehttps://modernod.com/news/aggressive-steroid-therapy-improves-visual-outcomes-in-vogt-koyanagi-harada-disease/2480135/Aggressive treatment beginning with pulsed intravenous corticosteroids appears to improve visual outcomes of new-onset acute Vogt-Koyanagi-Harada (VKH) disease, researchers from Japan report, according to a report in Medscape. VKH d
- Johnson & Johnson Vision Introduces Next-Generation TearScience Activator Clear for Treatment of MGDhttps://modernod.com/news/johnson-johnson-vision-introduces-next-generation-tearscience-activator-clear-for-treatment-of-mgd/2480795/Johnson & Johnson Vision announced the availability of the next-generation TearScience Activator Clear. Building on the legacy of the TearScience LipiFlow Thermal Pulsation System—a fully automated treatment for meibomian gland dysfunction (MGD)—Johnson & Johnson Vis
- Eye Foundation of America Hosts Fundraising Galahttps://modernod.com/news/eye-foundation-of-america-hosts-fundraising-gala/2482734/On April 12, the Eye Foundation of America is hosting a Spring fundraiser gala in New Rochelle, New York. Under the leadership of Surendra Sharma, MD and Rachana Shukla, MD, the group hopes to raise funds to help support a new state-of-the-art green hospital in India, as well
- Oculis and Euretina Announce Winner of Inaugural Ramin Tadayoni Awardhttps://modernod.com/news/oculis-and-euretina-announce-winner-of-inaugural-ramin-tadayoni-award/2482449/Oculis, in partnership with Euretina, has announced the first recipient of the Ramin Tadayoni Award: Dr. Andrea Govetto, MD, PhD. The award honors the memory of Oculis' late Chief Scientific Officer and renowned retina specialist, Professor Ramin Tadayoni, MD, who passed away unexpectedly ear
- Inaugural Eyecelerator Innovation Award Presented to Regeneron Executiveshttps://modernod.com/news/inaugural-eyecelerator-innovation-award-presented-to-regeneron-executives/2482404/Leonard Schleifer, MD, PhD, and George Yancopoulos, MD, PhD, of Regeneron Pharmaceuticals were awarded the first Eyecelerator Innovation Award. "This year's Eyecelerator Innovation Award honors the remarkable physician-led, science-dr
- NEI Director Highlights Metabolomics as an Approach to Understanding Glaucomahttps://modernod.com/news/nei-director-highlights-metabolomics-as-an-approach-to-understanding-glaucoma/2481982/The National Eye Institute (NEI) announced that NEI Director Michael F. Chiang, MD, featured recent research by NEI grantee Louis Pasquale, MD, in a National Institute of Health Director’s Blog post. Dr. Pasquale in collaboration with Jae Hee Kang, ScD, and Oana Zeleznik, PhD, explored 369